Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,438,726 shares of the medical research company's stock after acquiring an additional 59,426 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 1.34% of IQVIA worth $481,380,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in IQVIA in the 4th quarter worth about $236,120,000. American Century Companies Inc. grew its holdings in shares of IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after purchasing an additional 905,960 shares during the last quarter. FMR LLC increased its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $249.05.
View Our Latest Research Report on IQV
IQVIA Stock Down 2.7 %
Shares of NYSE IQV traded down $4.79 during midday trading on Monday, hitting $172.60. 590,474 shares of the stock traded hands, compared to its average volume of 1,296,647. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $169.54 and a one year high of $253.84. The business has a 50 day moving average price of $193.15 and a two-hundred day moving average price of $206.05. The company has a market cap of $30.43 billion, a PE ratio of 22.96, a P/E/G ratio of 1.99 and a beta of 1.50.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
